Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wei Garofolo

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Bioanalysis|November 12, 2014
Recommendations on incurred sample stability (ISS) by GCCSteve Lowes, Richard LeLacheur, Ronald Shoup, et al.
Bioanalysis|October 24, 2012
Conference report: 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilarsRobert Nicholson, Steve Lowes, Maria Cruz Caturla, et al.
Bioanalysis|November 22, 2014
7th GCC Insights: incurred samples use; fit-for-purpose validation, solution stability, electronic laboratory notebook and hyperlipidemic matrix testingMario Rocci, Steve Lowes, Ronald Shoup, et al.
Bioanalysis|August 18, 2025
17th GCC Closed Forum: Integrative Bioanalysis, Patient-centric Sampling, Emerging Technologies, Data Integrity, Sample Reconciliation, Discrepancies of ELISpot Data, Cross-validation Harmonization, Ultrasensitive Platforms for ADA Assays, Remote Regulatory Assessments, Shedding Assays by PCR, and Biomarker Tissue AssaysJennifer Zimmer, Mark O'dell, Derrick Johnson, et al.
Bioanalysis|June 15, 2022
Recommendations on qPCR/ddPCR assay validation by GCCMark Wissel, Martin Poirier, Christina Satterwhite, et al.
Bioanalysis|February 9, 2022
Recommendations on ELISpot assay validation by the GCCRafiq Islam, Jennifer Vance, Martin Poirier, et al.
Bioanalysis|February 27, 2016
9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooksRoger Hayes, Richard LeLacheur, Isabelle Dumont, et al.
Bioanalysis|April 18, 2019
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysisRafiq Islam, Sumit Kar, Hanna Ritzén, et al.
Bioanalysis|October 1, 2019
GCC Consolidated Feedback to ICH on the 2019 ICH M10 Bioanalytical Method Validation Draft GuidelineCorey Nehls, Michael Buonarati, Stephanie Cape, et al.
Bioanalysis|December 16, 2014
8th GCC: consolidated feedback to US FDA on the 2013 draft FDA guidance on bioanalytical method validationJoseph Bower, Douglas Fast, Fabio Garofolo, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Bioanalysis|November 12, 2014
Recommendations on incurred sample stability (ISS) by GCCSteve Lowes, Richard LeLacheur, Ronald Shoup, et al.
Bioanalysis|October 24, 2012
Conference report: 6th GCC focus on LBA: critical reagents, positive controls and reference standards; specificity for endogenous compounds; biomarkers; biosimilarsRobert Nicholson, Steve Lowes, Maria Cruz Caturla, et al.
Bioanalysis|November 22, 2014
7th GCC Insights: incurred samples use; fit-for-purpose validation, solution stability, electronic laboratory notebook and hyperlipidemic matrix testingMario Rocci, Steve Lowes, Ronald Shoup, et al.
Bioanalysis|August 18, 2025
17th GCC Closed Forum: Integrative Bioanalysis, Patient-centric Sampling, Emerging Technologies, Data Integrity, Sample Reconciliation, Discrepancies of ELISpot Data, Cross-validation Harmonization, Ultrasensitive Platforms for ADA Assays, Remote Regulatory Assessments, Shedding Assays by PCR, and Biomarker Tissue AssaysJennifer Zimmer, Mark O'dell, Derrick Johnson, et al.
Bioanalysis|June 15, 2022
Recommendations on qPCR/ddPCR assay validation by GCCMark Wissel, Martin Poirier, Christina Satterwhite, et al.
Bioanalysis|February 9, 2022
Recommendations on ELISpot assay validation by the GCCRafiq Islam, Jennifer Vance, Martin Poirier, et al.
Bioanalysis|February 27, 2016
9th GCC closed forum: CAPA in regulated bioanalysis; method robustness, biosimilars, preclinical method validation, endogenous biomarkers, whole blood stability, regulatory audit experiences and electronic laboratory notebooksRoger Hayes, Richard LeLacheur, Isabelle Dumont, et al.
Bioanalysis|April 18, 2019
Recommendations for classification of commercial LBA kits for biomarkers in drug development from the GCC for bioanalysisRafiq Islam, Sumit Kar, Hanna Ritzén, et al.
Bioanalysis|October 1, 2019
GCC Consolidated Feedback to ICH on the 2019 ICH M10 Bioanalytical Method Validation Draft GuidelineCorey Nehls, Michael Buonarati, Stephanie Cape, et al.
Bioanalysis|December 16, 2014
8th GCC: consolidated feedback to US FDA on the 2013 draft FDA guidance on bioanalytical method validationJoseph Bower, Douglas Fast, Fabio Garofolo, et al.
Pageof 3